Trial · NCT04335123
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment-related Adverse Events as Assessed by Protocol Definition of AE | 14 days of losartan treatment | Safety will be reported based on Protocol defined AEs. For the purpose of this protocol, an AE will be defined as as any untoward medical occurrence in a subject during the study listed under DMSB - Anticipated Adverse Events and Grading Scale section of this protocol as well as safety monitoring data listed on protocol table 1 as well as stoppage criteria for losartan. The event does not necessarily have a causal relationship with the treatment. AEs will be collected for both study groups, treatment and control from the time the ICF is signed until the subject completes study participation. |
| Secondary | Number of Days on Supplemental Oxygen in Respiratory Failure Due to COVID-19 | 14 days of losartan treatment | Number of days on supplemental oxygen in respiratory failure due to COVID-19 |
| Secondary | Number of Participants With Mechanical Ventilation Use | 14 days of losartan treatment | Number of participants with mechanical ventilation use |
| Secondary | Days on Mechanical Ventilation | 14 days of losartan treatment | Days on mechanical ventilation |
| Secondary | Number of Participants With Non-invasive Positive Pressure Ventilation or Heated High Flow Nasal Cannula Use | 14 days of losartan treatment | Number of participants with non-invasive positive pressure ventilation or heated high flow nasal cannula use |
| Secondary | Days on Non-invasive Positive Pressure Ventilation or High Flow Nasal Cannula | 14 days of losartan treatment | Days on non-invasive positive pressure ventilation or high flow nasal cannula |
| Secondary | Number of Participants With Transfer to ICU From Non-ICU Hospital Bed | 14 days of losartan treatment | Number of participants with transfer to ICU from non-ICU hospital bed |
| Secondary | ICU Length of Stay (Days) | 14 days of losartan treatment | ICU length of stay (days) |
| Secondary | in Hospital Mortality Rate | 14 days after study enrollment | in hospital mortality rate |
| Secondary | Hospital Length of Stay (Days) | from enrollment through hospital discharge | Hospital length of stay (days) |
| Secondary | Cumulative Number of Participants With of Severe Adverse Events | 14 days of losartan treatment | Cumulative number of participants with severe adverse events |
| Secondary | Number of Participants With Increase of Supplemental Oxygen Needs From Baseline. | 14 days of losartan treatment | Number of participants with increase in supplemental oxygen needs from baseline. |
| Secondary | Number of Participants With Medications With Possible Antiviral Activity (Hydroxychloroquine, Lopinavir/Ritonavir, Ribavirin or Remdesivir) or Adjunctive Therapy Use (e.g., Tocilizumab) | 14 days of losartan treatment | Number of participants with medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab) |
| Secondary | Number of Participants With Extracorporeal Membrane Oxygenation Use | 14 days of losartan treatment | Number of participants with extracorporeal membrane oxygenation use |
| Secondary | Number of Participants With Renal Replacement Therapy Use | 14 days of losartan treatment | Number of participants with renal replacement therapy use |
| Secondary | Number of Participants With Intolerance to High Dose (50mg) Losartan After Tolerating 25mg | 14 days of losartan treatment | Number of participants with intolerance to high dose (50mg) losartan after tolerating 25mg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04335123/registered